Search For "serum institute"
India to procure over 30 crore COVID-19 vaccine doses per month by January
Updated : 4 years, 7 months ago IST
New Delhi [India], October 16 (ANI): India will have a vaccine capacity of 28 crore doses this month, which includes 22 crore Serum Institute of India's Covishield and 6 crore doses of Bharat Biotech Biotech's Covaxin and production of 60 lakh Zydus Cadila's ZyCoV-D doses are also ready,
Read More
SII CEO Poonawalla thanks PM Modi, UK PM Johnson after no quarantine requi
Updated : 4 years, 7 months ago IST
New Delhi [India], October 8 (ANI): Serum Institute India (SII) CEO Adar Poonawalla thanked Prime Minister Narendra Modi and UK Prime Minister Boris Johnson after the UK Government announced no quarantine for fully vaccinated Indian travellers in the UK from October 11.
Read More
Serum Institute to send 10 lakh doses of Covishield to Nepal, Myanmar, Ban
Updated : 4 years, 7 months ago IST
New Delhi [India], October 7 (ANI): Serum Institute of India will export 10 lakh Covishield doses each to Nepal, Myanmar and Bangladesh, to help them fight against the pandemic, sources said.
Read More
SII aims to supply 21.50 crore doses of Covishield vaccine in October: Sou
Updated : 4 years, 7 months ago IST
Pune (Maharashtra) [India], October 1 (ANI): Serum Institute of India (SII) has supplied 78 crore doses of its COVID-19 vaccine Covishield so far and its target is to supply almost 21.50 crore doses in the month of October, informed the sources to ANI on Friday.
Read More
India to procure 27-28 crore COVID-19 vaccine doses in October: Sources
Updated : 4 years, 7 months ago IST
New Delhi [India], September 30 (ANI): India would have 27-28 crore COVID-19 vaccine doses of Serum Institute of India's Covishield and Bharat Biotech's Covaxin in the month of October, said government sources.
Read More
There should no vaccine discrimination, Covishield is fully certified, say
Updated : 4 years, 8 months ago IST
New Delhi [India], September 22 (ANI): The United Kingdom has recognised Serum Institute of India-manufactured Covid-19 vaccine Covishield in its new travel rules but has not removed quarantine restrictions concerning Indians.
Read More
SII announces strategic partnership with Biocon Biologics
Updated : 4 years, 8 months ago IST
New Delhi [India], September 17 (ANI): Hoping to strengthen India's position as a global vaccine and biologics manufacturing powerhouse, COVID-19 vaccine Covishield maker Serum Institute of India (SII) announced a strategic alliance with biopharmaceutical company Biocon Biologics Limited (BB
Read More
Biocon Biologics, Serum Institute Life Sciences enter strategic alliance
Updated : 4 years, 8 months ago IST
Bengaluru (Karnataka) [India], Sep 17 (ANI): Biocon Biologics Ltd (BBL) and Serum Institute Life Sciences (SILS) have announced a strategic alliance in a bid to make a significant impact on global healthcare through vaccines and biologics.
Read More
Biocon Biologics to offer 15 pc stake to Serum Institute Life Sciences at
Updated : 4 years, 8 months ago IST
Bengaluru (Karnataka) [India], September 17 (ANI): Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS) announced a strategic alliance on Thursday and BBL said it will offer around 15 per cent stake to SILS at a post-money valua
Read More
PM Modi, Mamata Banerjee, Adar Poonawala in Time's 100 Most Influential Pe
Updated : 4 years, 8 months ago IST
New Delhi [India], September 15 (ANI): Prime Minister Narendra Modi, West Bengal Chief Minister Mamata Banerjee and Serum Institute of India (SII) CEO Adar Poonawala have been listed in the Time Magazine's 100 Most Influential People of 2021.
Read More
SII acquires 50 pc stake in pharma packaging firm Schott Kaisha
Updated : 4 years, 9 months ago IST
Pune (Maharashtra) [India], August 17 (ANI): Serum Institute of India (SII) acquired a 50 pc stake of SCHOTT Kaisha to become SCHOTT's joint venture partner and secure pharma packaging supply, Serum Institute of India announced on Tuesday.
Read More
Mixing two different vaccines of COVID-19 is very risky: Cyrus Poonawalla
Updated : 4 years, 9 months ago IST
Pune (Maharashtra) [India], August 14 (ANI): Mixing two different vaccines of COVID-19 is a very risky decision and it is must be discouraged, said Cyrus Poonawalla, chairman of Serum Institute of India (SII) on Friday.
Read More